Development and Translation of Medical Technologies to Reduce Health Disparities (R43/R44) | Apply Online

Frequently Asked Questions (FAQs)

What is the purpose of the funding opportunity RFA-EB-11-001 (R43/R44)?

This NIH Small Business Innovation Research (SBIR) funding opportunity supports small businesses developing and translating practical medical technologies into real-world use in communities that experience health disparities. The central aim is to fund innovations that measurably reduce gaps in healthcare access and health outcomes, especially by focusing on solutions that can realistically be adopted and sustained in the settings where disparity populations receive care.

What does "reduce health disparities" mean in the context of this FOA?

In this FOA, reducing health disparities means creating and translating medical technologies that lead to measurable improvements in both access to healthcare and health outcomes for populations that have been historically underserved. The emphasis is not simply on improving healthcare in general, but on closing specific gaps affecting disparity populations.

Is this opportunity looking for early prototypes only, or solutions ready for real-world use?

The FOA is not just looking for a clever prototype. It is looking for solutions that can cross the translation gap and actually work in real care environments serving disparity populations. Applicants are expected to focus on practical adoption and sustainability, not only technical performance under ideal conditions.

Who is eligible to apply?

Eligibility is limited to small businesses, because this is an NIH SBIR opportunity using the R43/R44 mechanism.

What types of technologies are encouraged under this FOA?

The FOA supports applied medical technologies intended to reduce health disparities. Examples described include devices, diagnostics, monitoring tools, point-of-care systems, health IT-enabled tools, and other applied medical technologies, as long as the project is explicitly positioned to reduce health disparities (not merely improve healthcare broadly).

What qualities does NIH emphasize for the technologies supported by this announcement?

The technologies should be effective, affordable, culturally acceptable, and deliverable to the people who need them. Reviewers are likely to expect applicants to address real-world usability and adoption factors, not just laboratory performance.

What kinds of real-world constraints should applicants plan for?

The FOA highlights practical barriers and adoption realities in clinics and community settings, such as cost constraints, workflow fit, patient acceptability, and infrastructure limitations. It also flags barriers that can affect delivery and uptake, including language, health literacy, transportation challenges, limited broadband, and limited access to specialists.

Is a collaboration required to be considered responsive?

Yes. A defining requirement is a formal collaboration with a healthcare provider or another healthcare organization that serves a health disparity population. To be considered responsive, that collaboration must be active during both Phase I and Phase II.

What does "formal collaboration" imply for an application?

Based on the FOA description, a formal collaboration implies a clearly defined partner relationship with roles and responsibilities and a credible plan for how the partner will contribute across the project. The partner is expected to be involved during both Phase I and Phase II, helping ensure the work is grounded in the needs and operational constraints of the target setting and population.

Why does the FOA require an active partner in both Phase I and Phase II?

The collaboration requirement is a major design feature intended to push small businesses to co-develop and test solutions alongside organizations that understand the target population and care environment. This helps keep development focused on solutions that can be implemented, accepted, and sustained in real-world settings serving disparity populations.

What is the SBIR R43/R44 phased structure described in this opportunity?

The award uses the SBIR phased structure. Phase I generally supports early feasibility work, proof-of-concept, initial prototyping, and early validation. Phase II supports further R&D, refinement, and more substantial testing toward a product that is ready for broader deployment or commercialization.

How does the Phase I/Phase II structure align with the FOA's translation goal?

The phased approach aligns with moving a disparity-focused technology from early development into translation, including iterative improvements informed by the partner organization. This supports building something that works in real care settings and can be sustained beyond development.

Does this program require cost sharing or matching funds?

No. The opportunity explicitly states there is no cost sharing or matching requirement.

What agency administers this grant program?

The program is administered by the National Institutes of Health (NIH) and is listed as a discretionary grant program.

What is the Funding Opportunity Number and mechanism for this announcement?

The Funding Opportunity Number is RFA-EB-11-001, and the mechanism is NIH SBIR under R43/R44.

Is this funding opportunity still open?

No. The information provided indicates the opportunity has passed its final closing date (January 7, 2012) and has an archive date of February 7, 2012, meaning it is no longer open for applications under that specific announcement.

When was the opportunity posted, and what were the closing dates?

It was posted and created on March 11, 2011. The original and final closing date was January 7, 2012. The archive date is February 7, 2012.

Which CFDA program areas are associated with this opportunity?

The listing associates the program with multiple CFDA numbers: 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health), 93.307 (Minority Health and Health Disparities Research), 93.389 (National Center for Research Resources), and 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research).

Where is the full announcement referenced?

The full announcement is referenced as an archived notice accessible through the NIH Grants Guide link provided in the listing.

Who should be contacted for access issues or technical problems with the notice?

For issues accessing the announcement electronically or problems linking to the funding notice, the listed route is the NIH Office of Extramural Research (OER) webmaster, using the email address provided in the listing.

What is the main takeaway for applicants based on the information provided?

This FOA is best understood as an NIH SBIR pathway aimed at pushing small business-developed medical technologies into real care settings that serve disparity populations, with a firm expectation of ongoing, formal partnership with a provider or healthcare organization to ensure the solution is practical, acceptable, deliverable, and capable of reducing measurable gaps in access and outcomes.